# EDGAR Filing Document

**Accession Number:** 0000704532
**File Stem:** 0001193125-26-206707
**Filing Date:** 2026-5
**Character Count:** 127666
**Document Hash:** 752fcebf4c07672659b9f75cdce8f7e8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-206707.hdr.sgml**: 20260505

**ACCESSION NUMBER**: 0001193125-26-206707

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 89

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260505

**DATE AS OF CHANGE**: 20260505

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ONTO INNOVATION INC.
- **CENTRAL INDEX KEY:** 0000704532
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEASURING & CONTROLLING DEVICES, NEC [3829]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 942276314
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1226

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39110
- **FILM NUMBER:** 26944387

**BUSINESS ADDRESS:**
- **STREET 1:** 16 JONSPIN ROAD
- **CITY:** WILMINGTON
- **STATE:** MA
- **ZIP:** 01887
- **BUSINESS PHONE:** 9782536200

**MAIL ADDRESS:**
- **STREET 1:** 16 JONSPIN ROAD
- **CITY:** WILMINGTON
- **STATE:** MA
- **ZIP:** 01887

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Onto Innovation Inc.
- **DATE OF NAME CHANGE:** 20191025

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NANOMETRICS INC
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'? 10-Q

[**<u>**Table of Contents**</u>**](#toc_page)

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

------

**FORM** 10-Q

------

**(Mark One)**

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**For the Quarterly Period Ended** **March 31,** 2026

**OR**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from to**

**Commission File No.** 001-39110

------

ONTO INNOVATION INC.

**(Exact name of registrant as specified in its charter)**

------

Delaware 94-2276314 <br> (State or other jurisdiction ofincorporation or organization) (I.R.S. EmployerIdentification Number)

16 Jonspin Road**,** Wilmington**,** Massachusetts 01887

**(Address of principal executive offices, including zip code)**

**Registrant's telephone number, including area code: (**978**)** 253-6200

**Securities registered pursuant to Section 12(b) of the Act**

---

| | | |
|:---|:---|:---|
| **Title of Each Class** | **Trading Symbol(s)** | **Name of Each Exchange on Which Registered** |
| Common Stock, $0.001 par value per share | ONTO | New York Stock Exchange (NYSE) |

---

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of outstanding shares of the registrant's Common Stock on May 1, 2026 was 49,743,567.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
| Item No. |  | Page |
|  | **PART I FINANCIAL INFORMATION** |  |
| Item 1. | [Financial Statements (unaudited)](#condensed_consolidated_statements_operat) | 1 |
|  | &nbsp;&nbsp;&nbsp;&nbsp;[Condensed Consolidated Statements of Operations for the three months ended March 31, 2026 and March 29, 2025](#condensed_consolidated_statements_operat) | 1 |
|  | &nbsp;&nbsp;&nbsp;&nbsp;[Condensed Consolidated Statements of Comprehensive Income for the three months ended March 31, 2026 and March 29, 2025](#condensed_consolidated_statements_compre) | 2 |
|  | [Condensed Consolidated Balance Sheets at March 31, 2026 and January 3, 2026](#condensed_consolidated_balance_sheets) | 3 |
|  | [Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and March 29, 2025](#condensed_consolidated_statements_cash_f) | 4 |
|  | &nbsp;&nbsp;&nbsp;&nbsp;[Condensed Consolidated Statements of Stockholders' Equity for the three months ended March 31, 2026 and March 29, 2025](#condensed_consolidated_stockholders_equi) | 5 |
|  | [Notes to Condensed Consolidated Financial Statements](#notes_to_condensed_consolidated_financia) | 6 |
| Item 2. | [Management's Discussion and Analysis of Financial Condition and Results of Operations](#item_2_managements_discussion_analysis_f) | 17 |
| Item 3. | [Quantitative and Qualitative Disclosures about Market Risk](#item_3_quantitative_qualitative_disclosu) | 23 |
| Item 4. | [Controls and Procedures](#item_4_controls_procedures) | 23 |
|  | **PART II OTHER INFORMATION** |  |
| Item 1. | [Legal Proceedings](#item_1_legal_proceedings) | 24 |
| Item 1A. | Risk Factors | 24 |
| Item 2. | [Unregistered Sales of Equity Securities and Use of Proceeds](#item_2_unregistered_sales_equity_securit) | 24 |
| Item 3. | [Defaults Upon Senior Securities](#item_3_defaults_upon_senior_securities) | 25 |
| Item 4. | [Mine Safety Disclosures](#item_4_mine_safety_disclosures) | 25 |
| Item 5. | [Other Information](#item_5_or_information) | 25 |
| Item 6. | [Exhibits](#item_6__exhibits) | 26 |

---

[Signatures](#signatures)

------

[**<u>**Table of Contents**</u>**](#toc_page)

**PART I FINANCIAL INFORMATION**

**Item 1. Financial Statements**

**ONTO INNOVATION INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

**(In thousands, except per share data)**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 29,** |
|  | **2026** | **2025** |
| Revenue | $291949 | $266607 |
| Cost of revenue | 145560 | 123374 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 146389 | 143233 |
| Operating expenses: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | 35098 | 28030 |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales and marketing | 21459 | 19716 |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 31409 | 22785 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization | 19700 | 8445 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring and other | 5209 | 1123 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 112875 | 80099 |
| Operating income | 33514 | 63134 |
| Other income, net |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income, net | 5102 | 9266 |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency exchange losses | (461) | (762) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other (expense) income, net | (103) | 19 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other income, net | 4538 | 8523 |
| Income before provision for income taxes | 38052 | 71657 |
| Provision for income taxes | 4302 | 7562 |
| Net income | $33750 | $64095 |
| Earnings per share: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | $0.68 | $1.30 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | $0.67 | $1.30 |
| Weighted average number of shares outstanding: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | 49742 | 49180 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | 50004 | 49408 |

---

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**ONTO INNOVATION INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME**

**(In thousands)**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 29,** |
|  | **2026** | **2025** |
| Net income | $33750 | $64095 |
| Other comprehensive (loss) income, net of tax: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in net unrealized (losses) gains on available-for-sale marketable securities | (659) | 338 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in currency translation adjustments | (1860) | 2013 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other comprehensive (loss) income, net of tax | (2519) | 2351 |
| Total comprehensive income | $31231 | $66446 |

---

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**ONTO INNOVATION INC.**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

**(In thousands)**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | **March 31,<br>2026** | **January 3,<br>2026** |
| **ASSETS** |  |  |
| *Current Assets:* |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $252247 | $346119 |
| &nbsp;&nbsp;&nbsp;&nbsp;Marketable securities | 401917 | 293503 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net of allowance of $2,453 at March 31, 2026 and $2,462 at January 3, 2026. | 306564 | 268932 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories, net | 316026 | 298264 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 42964 | 61217 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 1319718 | 1268035 |
| Property, plant and equipment, net | 123818 | 127184 |
| Goodwill | 643468 | 644015 |
| Identifiable intangible assets, net | 278399 | 298098 |
| Deferred income taxes | 4449 | 3864 |
| Other assets | 26514 | 26545 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $2396366 | $2367741 |
| **LIABILITIES AND STOCKHOLDERS' EQUITY** |  |  |
| *Current liabilities:* |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $105522 | $107685 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities | 46421 | 48544 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue | 31439 | 31781 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other current liabilities | 31066 | 30936 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 214448 | 218946 |
| Deferred and other tax liabilities | 20272 | 20401 |
| Other non-current liabilities | 29458 | 27747 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 264178 | 267094 |
| Commitments and contingencies |  |  |
| Stockholders' equity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock, $0.001 par value, 97,000 shares authorized, 49,744 and 49,702 issued and outstanding at March 31, 2026 and January 3, 2026, respectively. | 50 | 50 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 1367143 | 1366833 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | (12540) | (10021) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated earnings | 777535 | 743785 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 2132188 | 2100647 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $2396366 | $2367741 |

---

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**ONTO INNOVATION INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(In thousands)**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 29,** |
|  | **2026** | **2025** |
| Cash flows from operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income | $33750 | $64095 |
| Adjustments to reconcile net income to net cash and cash equivalents provided by operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangibles | 19700 | 8445 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accretion of discount on marketable securities | (234) | (1537) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation | 5784 | 4395 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation | 7011 | 6814 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provision for inventory valuation | 1191 | 1534 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | 14 | (3774) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other, net | 679 | 1171 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities | (41573) | 10837 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash and cash equivalents provided by operating activities | 26322 | 91980 |
| Cash flows from investing activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchases of marketable securities | (179508) | (208526) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from maturities and sales of marketable securities | 70487 | 203012 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchases of property, plant and equipment | (3585) | (8233) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchases of non-marketable equity securities |  | (8000) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Acquisition related adjustments |  | (57) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash and cash equivalents used in investing activities | (112606) | (21804) |
| Cash flows from financing activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchases and retirement of common stock |  | (75015) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tax payments related to shares withheld for share-based compensation plans | (6701) | (8684) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Issuance of shares through share-based compensation plans |  | 4179 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash and cash equivalents used in financing activities | (6701) | (79520) |
| Effect of exchange rate changes on cash and cash equivalents | (887) | 126 |
| Net decrease in cash and cash equivalents | (93872) | (9218) |
| Cash and cash equivalents at beginning of period | 346119 | 212945 |
| Cash and cash equivalents at end of period | $252247 | $203727 |
| Supplemental disclosure of cash flow information: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes paid (net of refunds) | $1569 | $770 |

---

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**ONTO INNOVATION INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY**

**(In thousands)**

**(Unaudited)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | **Additional <br>Paid-in** | **Accumulated<br>Other<br>Comprehensive** | **Accumulated** |  |
|  | **Shares** | **Amount** | **Capital** | **Loss** | **Earnings** | **Total** |
| Balance at January 3, 2026 | 49702 | $50 | $1366833 | $(10021) | $743785 | $2100647 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income |  |  |  |  | 33750 | 33750 |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation |  |  | 7011 |  |  | 7011 |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of shares through share-based compensation plans, net | 73 |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of common stock | (31) |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation plan withholdings |  |  | (6701) |  |  | (6701) |
| &nbsp;&nbsp;&nbsp;&nbsp;Currency translation |  |  |  | (1860) |  | (1860) |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized loss on investments |  |  |  | (659) |  | (659) |
| Balance at March 31, 2026 | 49744 | $50 | $1367143 | $(12540) | $777535 | $2132188 |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | **Additional <br>Paid-in** | **Accumulated<br>Other<br>Comprehensive** | **Accumulated** |  |
|  | **Shares** | **Amount** | **Capital** | **Loss** | **Earnings** | **Total** |
| Balance at December 28, 2024 | 49238 | $49 | $1275146 | $(13863) | $664550 | $1925882 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income |  |  |  |  | 64095 | 64095 |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation |  |  | 6814 |  |  | 6814 |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of shares through share-based compensation plans, net | 140 |  | 4179 |  |  | 4179 |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of common stock | (541) |  | (17491) |  | (57524) | (75015) |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation plan withholdings |  |  | (8684) |  |  | (8684) |
| &nbsp;&nbsp;&nbsp;&nbsp;Currency translation |  |  |  | 2013 |  | 2013 |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized gain on investments |  |  |  | 338 |  | 338 |
| Balance at March 29, 2025 | 48837 | $49 | $1259964 | $(11512) | $671121 | $1919622 |

---

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**ONTO INNOVATION INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Unaudited)**

**NOTE 1. Basis of Presentation**

The accompanying interim unaudited Condensed Consolidated Financial Statements have been prepared by Onto Innovation Inc. (the "Company," "Onto Innovation," "we," "our" or "us") and in the opinion of management reflect all adjustments, consisting of normal recurring accruals, necessary for their fair presentation in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Update ("ASU") of the Financial Accounting Standards Board ("FASB"). Certain reclassifications have been made to prior-period amounts to conform to current-period presentation. The interim results for the three-month period ended March 31, 2026 are not necessarily indicative of results to be expected for the entire year or any future periods. This interim financial information should be read in conjunction with the financial statements and the notes thereto included in the Company's Annual Report on Form 10-K for the year ended January 3, 2026 (the "2025 Form 10-K") filed with the Securities and Exchange Commission on February 24, 2026. The accompanying Condensed Consolidated Balance Sheet at January 3, 2026 has been derived from the audited consolidated financial statements included in the 2025 Form 10-K.

On February 18, 2026, the Board of Directors changed the Company's fiscal year-end from a 52-53 week fiscal year ending on the Saturday closest to December 31 to a December 31 fiscal year-end. The Company made the fiscal year change on a prospective basis and will not adjust operating results for prior periods. Additionally, the Company has adopted calendar quarter fiscal period ends commencing with the first quarter ended March 31, 2026. The change affects the prior year comparability of the Company's fiscal quarters in 2025 and will result in shifts in the quarterly periods, which is not expected to have a material impact on our quarterly financial results. Our fiscal year ended January 3, 2026 was a 53-week fiscal year. The first quarter of the fiscal year ended January 3, 2026 ended on March 29, 2025. Throughout this document, the three-month period ended March 31, 2026 represents the quarterly period that commenced on January 4, 2026, the first day of our fiscal year, and ended on March 31, 2026. The three-month period ended March 29, 2025 represents the quarterly period that commenced on December 29, 2024 and ended on March 29, 2025.

**Use of Estimates**

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Estimates made by management include excess and obsolete inventory, fair value of assets acquired and liabilities assumed in a business combination, recoverability and useful lives of property, plant and equipment and identifiable intangible assets, recoverability of goodwill, recoverability of deferred tax assets, allowance for credit losses, liabilities for product warranty, share-based payments and liabilities for tax uncertainties. Actual results could differ from those estimates.

These estimates and assumptions are based on historical experience and on various other factors which the Company believes to be reasonable under the circumstances. The Company may engage third-party valuation specialists to assist with estimates related to the valuation of financial instruments, assets and stock awards associated with various contractual arrangements. Such estimates often require the selection of appropriate valuation methodologies and significant judgment. Actual results could differ from these estimates under different assumptions or circumstances and such differences could be material.

**Recent Accounting Pronouncements**

*Recently Adopted or Effective*

In July 2025, the FASB issued ASU 2025-05, "Financial Instruments - Credit Losses (Topic 326)," which simplifies the estimation of credit losses on current accounts receivable and current contract assets arising from transactions accounted for under Accounting Standards Codification 606, Revenue from Contracts with Customers. The guidance allows all entities to use a practical expedient to assume that the current conditions as of the balance sheet date will remain unchanged for the remaining life of the asset when developing a reasonable and supportable forecast as part of estimating expected credit losses on these assets. The guidance is effective for fiscal years beginning after December 15, 2025, and interim periods within those fiscal years. Early adoption is permitted. Entities that elect the practical expedient are required to apply the amendments prospectively. The

------

[**<u>**Table of Contents**</u>**](#toc_page)

Company adopted this ASU during the quarter ended March 31, 2026, with no material impact on the condensed consolidated financial statements.

*Updates Not Yet Effective*

In December 2025, the FASB issued ASU 2025-11, "Interim Reporting (Topic 270): Narrow-Scope Improvements," to clarify and reorganize U.S. GAAP interim reporting guidance to improve navigability, applicability, and consistency without changing the fundamental nature or volume of required interim disclosures. This amendment clarifies when ASC 270 is applicable, establishes a disclosure principle requiring disclosure of material events or changes occurring since the most recent annual reporting period, and consolidates into ASC Topic 270 a comprehensive list of interim disclosures required by other Codification Topics. The amendment also clarifies the form and content of interim financial statements, including guidance for condensed interim reporting. The amendment is effective for the Company for interim periods in 2028, with early adoption permitted. The impact of the adoption of the amendments in this update is not expected to be material to the Company's consolidated financial position and results of operations.

In December 2025, the FASB issued ASU 2025-10, "Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities*,"* to establish specific guidance for the recognition, measurement, presentation, and disclosure of government grants received to reduce diversity and increase consistency amongst business entities in accounting for such grants. This amendment amends ASC Topic 832 to require that a government grant received by a business entity should not be recognized as income until it is probable that a business entity will comply with the conditions attached to the grant and the grant will be received, with any grant related to an asset to be purchased, constructed or acquired such as long-lived assets or inventory to be recognized on the balance sheet as either deferred income or as an adjustment to the cost basis of the related asset, or the cost accumulation approach, as such costs are incurred. Any grant income or deferred income shall be recognized in earnings on a systematic and rational basis over the periods in which a business entity recognizes as expenses the costs for which the grant is intended to compensate, whereas any grants accounted for using the cost accumulation approach will not have a direct subsequent recognition in earnings, but rather reduced depreciation or amortization in accounting for the related asset. Entities are also required to present grants recognized in earnings separately under other income or deducted from the related expense, and provide disclosures of the nature of the government grant received, the accounting policies used to account for the grant, and the significant terms and conditions of the grant. The amendment is effective for the Company for annual and interim periods in 2029, with early adoption and multiple transition methods permitted. The Company is currently evaluating the potential impact of this standard on its consolidated financial statements.

In December 2025, the FASB issued ASU 2025-09, "Derivatives and Hedging (Topic 815): Hedge Accounting Improvements," to amend certain aspects of its hedge accounting guidance to better reflect an entity's risk management activities in the financial statements. The guidance expands the hedged risks permitted to be aggregated in a group of individual forecasted transactions and increases the variable price components eligible to be designated as the hedged risk in the forecasted purchase or sale of nonfinancial assets. For public business entities, the provisions of ASU 2025-09 are effective for fiscal years beginning after December 15, 2026. Early adoption is permitted. The Company is currently evaluating the potential impact of this standard on its consolidated financial statements.

In September 2025, the FASB issued ASU 2025-06, "Intangibles-Goodwill and Other-Internal Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software," which removes all references to software development stages and clarifies the threshold entities apply to begin capitalizing costs. ASU 2025-06 is effective for annual periods beginning after December 15, 2027 and interim reporting periods within those annual reporting periods. The ASU may be applied prospectively, retrospectively or through a modified transition approach with early adoption permitted. The Company is currently evaluating the potential impact of this standard on its consolidated financial statements.

In November 2024, the FASB issued ASU 2024-03, "Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40)," which requires additional disclosure of certain costs and expenses, including inventory purchases, employee compensation, selling expense and depreciation expense within the notes to financial statements. The guidance is effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact that the updated standard will have on its financial statements and related disclosures.

**NOTE 2. Acquisitions**

On November 17, 2025 (the "Acquisition Date"), the Company completed the previously announced acquisition of Semilab USA LLC ("Semilab USA"), pursuant to the Equity Purchase Agreement (the "Purchase Agreement"), dated as of June 27, 2025, by and among the Company, Semilab International Zrt. (the "Seller"), Semilab Zrt. and Semilab USA, as amended by the Amendment to Equity Purchase Agreement, dated October 9, 2025.

------

[**<u>**Table of Contents**</u>**](#toc_page)

The preliminary Acquisition Date fair value of consideration transferred consisted of the following:

---

| | |
|:---|:---|
|  | **At Acquisition Date** |
|  | **(in thousands, except per share data)** |
| Cash paid | $389052 |
| &nbsp;&nbsp;Issuance of common stock <sup>(1)</sup> | 81697 |
| &nbsp;&nbsp;Cash paid to extinguish Semilab USA's debt | 55892 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total purchase consideration | $526641 |
| <sup>(1)</sup> The fair value is based on the issuance of 641,771 shares of the Company's common stock with a per share value of $127.30 on the Acquisition Date. | <sup>(1)</sup> The fair value is based on the issuance of 641,771 shares of the Company's common stock with a per share value of $127.30 on the Acquisition Date. |

---

The Company accounted for the acquisition of Semilab USA in accordance with ASC Topic 805, Business Combinations ("ASC 805"). The acquired assets and assumed liabilities were recorded at their estimated fair values. The Company determined the estimated fair values with the assistance of valuations performed by a third-party specialist, discounted cash flow analysis, and estimates made by management.

The acquisition strengthens the Company's capabilities in inline wafer contamination monitoring, materials characterization, and unique surface charge metrology. The goodwill recognized reflects the anticipated benefits from expanding the Company's product portfolio and its growth opportunities in both new and existing markets. As the purchase price exceeded the fair value of Semilab USA's identifiable net assets, goodwill was recorded in connection with the transaction. The Company does not expect the goodwill to be deductible for income tax purposes.

A portion of the overall purchase price was allocated to acquired intangible assets. Amortization expense associated with acquired intangible assets is not deductible for tax purposes. Therefore, a deferred tax liability of $46.6 million was established primarily for the future amortization of these intangibles and is included in "other long-term liabilities" in the table below.

The inventory fair value step-up is non-recurring and is recognized as an increase to cost of revenue as the related inventory is sold. For the year ended January 3, 2026, the Company recognized $4.0 million of expense related to the step-up. During the three months ended March 31, 2026, the Company recognized $6.1 million of expense related to the step-up. The remaining balance of approximately $3.0 million is expected to be recognized over the estimated sell-through period of one year following the Acquisition Date.

The following table summarizes the preliminary purchase price allocation of the fair values of the assets acquired and liabilities assumed:

---

| | |
|:---|:---|
|  | **At Acquisition Date** |
|  | **(in thousands)** |
| Cash and cash equivalents | $8876 |
| Accounts receivable | 14428 |
| Inventories | 33838 |
| Prepaid expenses and other current assets | 843 |
| Property, plant and equipment | 2058 |
| Intangible assets | 210000 |
| Other assets | 3592 |
| Accounts payable | (487) |
| Accrued expenses and other current liabilities | (8270) |
| Other long-term liabilities | (51668) |
| Total identifiable net assets | 213210 |
| &nbsp;&nbsp;&nbsp;&nbsp;Goodwill | 313431 |
| Total purchase consideration | $526641 |

---

------

[**<u>**Table of Contents**</u>**](#toc_page)

The following table sets forth the preliminary amounts, allocated to the intangible assets identified and their estimated useful lives as of the Acquisition Date:

---

| | | |
|:---|:---|:---|
|  | **At Acquisition Date** | **At Acquisition Date** |
|  | **Fair Value** | **Weighted Average Useful Life** |
|  | **(in thousands)** | **(in years)** |
| Developed technology | $103000 | 7.0 |
| Customer relationships | 82000 | 6.0 |
| Backlog | 20000 | 1.3 |
| Tradename | 5000 | 8.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total amortizable intangible assets | $210000 |  |

---

The developed technology intangible assets were valued using the relief-from-royalty method under the income approach, which estimates value based on the royalty a market participant would pay to license the technology. Under this approach, the after-tax royalty savings attributable to ownership represent the economic benefit of the asset. The key assumptions used in the valuation included the estimated royalty rate, projected revenue attributable to the developed technology, the expected useful life of the asset, and a discount rate reflecting the risks associated with the projected cash flows. The assets are amortized on a straight-line basis over their estimated 7-year useful life, which approximates the expected pattern of economic benefits.

The customer relationships and backlog intangible assets were valued using the multi-period excess earnings method under the income approach, which isolates the net cash flows attributable to each asset and discounts them to present value. Significant assumptions included projected customer revenue and attrition rates, estimated operating margins, contributory asset charges, the expected useful life of the asset, and a discount rate reflecting the risks associated with the asset-specific cash flows. The customer relationship asset is amortized on a straight-line basis over its 6-year estimated life to reflect the pattern of expected economic benefits. The backlog asset is amortized on a straight-line basis over its 1.3 year estimated life to reflect the pattern of expected economic benefits.

There were no significant contingencies assumed as part of the acquisition.

The purchase price allocation for the Semilab USA acquisition is preliminary and reflects management's current estimates of the fair value of the assets acquired and liabilities assumed in accordance with ASC 805. The Company is still evaluating certain items within the measurement period, including the final determination of the working capital adjustment, which remains subject to post-closing review procedures outlined in the Purchase Agreement. Accordingly, the provisional amounts recognized for the acquired net assets are subject to change during the remainder of the measurement period (which will not exceed 12 months from the Acquisition Date). Any such revisions or changes may be material.

From the Acquisition Date through January 3, 2026, Semilab USA contributed $8.6 million of revenue and an operating loss of $6.2 million to the Company's consolidated results. During the three months ended March 31, 2026, Semilab USA contributed $27.1 million of revenue and operating income of $13.4 million to the Company's consolidated results.

**NOTE 3. Fair Value Measurements**

*Recurring Fair Value Measurements*

The following tables present information about the Company's assets and liabilities that are regularly measured and carried at fair value on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value, which is described further within *Note 4 Fair Value Measurements* to the consolidated financial statements in the Company's Annual Report on Form 10-K for the fiscal year ended January 3, 2026:

------

[**<u>**Table of Contents**</u>**](#toc_page)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** |
|  | **Cash and Cash Equivalents** | **Cash and Cash Equivalents** | **Cash and Cash Equivalents** | **Marketable Securities** | **Marketable Securities** | **Marketable Securities** |
|  | **Level 1** | **Level 2** | **Total** | **Level 1** | **Level 2** | **Total** |
|  | **(in thousands)** | **(in thousands)** | **(in thousands)** | **(in thousands)** | **(in thousands)** | **(in thousands)** |
| Assets: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Federal and municipal notes and bonds | $— | $45840 | $45840 | $— | $177599 | $177599 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash | 156797 |  | 156797 |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Money market funds | 2068 |  | 2068 |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certificates of deposit |  |  |  |  | 66194 | 66194 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commercial paper |  | 47542 | 47542 |  | 94339 | 94339 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corporate bonds |  |  |  |  | 63784 | 63784 |
| &nbsp;&nbsp;&nbsp;&nbsp; Foreign currency forward contracts |  |  |  |  | 884 | 884 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $158865 | $93382 | $252247 | $— | $402800 | $402800 |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **January 3, 2026** | **January 3, 2026** | **January 3, 2026** | **January 3, 2026** | **January 3, 2026** | **January 3, 2026** |
|  | **Cash and Cash Equivalents** | **Cash and Cash Equivalents** | **Cash and Cash Equivalents** | **Marketable Securities** | **Marketable Securities** | **Marketable Securities** |
|  | **Level 1** | **Level 2** | **Total** | **Level 1** | **Level 2** | **Total** |
|  | **(in thousands)** | **(in thousands)** | **(in thousands)** | **(in thousands)** | **(in thousands)** | **(in thousands)** |
| Assets: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Federal and municipal notes and bonds | $— | $40415 | $40415 | $— | $141401 | $141401 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash | 245130 |  | 245130 |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Money market funds | 5118 |  | 5118 |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certificates of deposit |  |  |  |  | 47339 | 47339 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commercial paper |  | 53373 | 53373 |  | 40357 | 40357 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corporate bonds |  | 2083 | 2083 |  | 64406 | 64406 |
| &nbsp;&nbsp;&nbsp;&nbsp; Foreign currency forward contracts |  |  |  |  | 89 | 89 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $250248 | $95871 | $346119 | $— | $293592 | $293592 |

---

Items classified within Level 1 of the fair value hierarchy are valued using quoted prices in active markets for identical assets or liabilities. The Company's marketable securities, comprised of Level 2 available-for-sale debt securities, are valued using observable inputs to quoted market prices, benchmark yields, reported trades, broker/dealer quotes or alternative pricing sources with reasonable levels of price transparency. The foreign currency forward contracts are primarily measured based on the foreign currency spot and forward rates quoted by the banks or foreign currency dealers.

There were no impairments of the Company's assets measured and carried at fair value during the three months ended March 31, 2026 and March 29, 2025. There were no changes in valuation techniques during the three months ended March 31, 2026 and March 29, 2025.

*Non-recurring Fair Value Measurements*

At March 31, 2026 and January 3, 2026, the Company held investments of $8.0 million in the equity of a privately-held company. This non-marketable equity investment is recorded at fair value on a non-recurring basis and is classified as a Level 3 asset in "Other assets" on the Condensed Consolidated Balance Sheets. This non-marketable equity investment is generally accounted for under the measurement alternative, defined as cost, less impairments, adjusted for subsequent observable price changes and is periodically assessed for impairment when events or circumstances indicate that decline in value may have occurred. As of March 31, 2026, there have been no impairments recorded for the non-marketable equity investment.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**NOTE 4. Marketable Securities**

At March 31, 2026 and January 3, 2026, marketable securities are categorized as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Amortized Cost** | **Gross Unrealized<br>Gains** | **Gross Unrealized<br>Losses** | **Estimated<br>Fair Value** |
|  | **(in thousands)** | **(in thousands)** | **(in thousands)** | **(in thousands)** |
| **March 31, 2026** |  |  |  |  |
| Federal and municipal notes and bonds | $177488 | $253 | $(142) | $177599 |
| Certificates of deposit | 66245 | 9 | (60) | 66194 |
| Commercial paper | 94381 | 5 | (47) | 94339 |
| Corporate bonds | 63802 | 71 | (88) | 63785 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total marketable securities | $401916 | $338 | $(337) | $401917 |
| **January 3, 2026** |  |  |  |  |
| Federal and municipal notes and bonds | $149004 | $551 | $(1) | $149554 |
| Certificates of deposit | 47243 | 95 |  | 47338 |
| Commercial paper | 32188 | 16 |  | 32204 |
| Corporate bonds | 64214 | 193 |  | 64407 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total marketable securities | $292649 | $855 | $(1) | $293503 |

---

As of March 31, 2026, all of the Company's marketable securities are available to the Company for use in its current operations. As a result, the Company has classified all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date. The following table shows the fair value of the Company's marketable securities, by contractual maturity, as of March 31, 2026:

---

| | | |
|:---|:---|:---|
|  | **March 31, 2026** | **January 3, 2026** |
|  | **Fair Value** | **Fair Value** |
|  | **(in thousands)** | **(in thousands)** |
| Due within one year | $326387 | $233043 |
| Due after one through five years | 75530 | 60460 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total marketable securities | $401917 | $293503 |

---

The aggregate fair value of marketable securities with unrealized losses was $175.5 million and $21.2 million as of March 31, 2026 and January 3, 2026, respectively. All unrealized losses are reported in Stockholders Equity under the caption "Accumulated other comprehensive loss." As of March 31, 2026 and January 3, 2026, 162 investments and 11 investments were in an unrealized loss position, respectively. All such investments have been in an unrealized loss position for less than a year and these losses are considered temporary. As of March 31, 2026 and January 3, 2026, three investments and two investments were in an unrealized loss position, respectively, for greater than a year. The Company has the ability and intent to hold these investments until a recovery of their amortized cost, which may not occur until maturity. The Company expects these securities are subject to minimal credit risk. As a result, the Company did not record any charges for credit-related impairments for its available-for-sale securities for the three months ended March 31, 2026 and March 29, 2025.

**NOTE 5. Derivative Instruments and Hedging Activities**

The Company, when it considers it to be appropriate, enters into forward contracts to hedge the economic exposure arising from foreign currency denominated transactions. These contracts are typically denominated in euro, Chinese renminbi, Japanese yen, Korean won, Singapore dollars and Taiwanese dollars. Foreign currency forward contracts are not designated as hedges for accounting purposes, and therefore, the change in fair value is recorded in "Other (expense) income, net," in the Condensed Consolidated Statements of Operations. The Company records its forward contracts at fair value in either "Prepaid expenses and other current assets" or "Other current liabilities" in the Condensed Consolidated Balance Sheets.

The dollar equivalent of the U.S. dollar forward contracts notional amount and related fair values as of March 31, 2026 and January 3, 2026 were as follows:

---

| | | |
|:---|:---|:---|
|  | **March 31, 2026** | **January 3, 2026** |
|  | **(in thousands)** | **(in thousands)** |
| Notional amount | $81775 | $47361 |
| Fair value of asset | $884 | $89 |

---

------

[**<u>**Table of Contents**</u>**](#toc_page)

**NOTE 6. Balance Sheet Components**

*Inventories*

Inventories, net of reserves are comprised of the following:

---

| | | |
|:---|:---|:---|
|  | **March 31, 2026** | **January 3, 2026** |
|  | **(in thousands)** | **(in thousands)** |
| Materials | $232079 | $208061 |
| Work-in-process | 62493 | 59764 |
| Finished goods | 21454 | 30439 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total inventories, net | $316026 | $298264 |

---

*Property, Plant and Equipment*

Property, plant and equipment, net is comprised of the following:

---

| | | |
|:---|:---|:---|
|  | **March 31, 2026** | **January 3, 2026** |
|  | **(in thousands)** | **(in thousands)** |
| Machinery and equipment | $95128 | $95151 |
| Land and building | 47718 | 47770 |
| Computer equipment and software | 41384 | 40635 |
| Leasehold improvements | 24583 | 24040 |
| Furniture and fixtures | 3921 | 3920 |
| &nbsp;&nbsp;Total property, plant and equipment, gross | 212734 | 211516 |
| Accumulated depreciation | (88916) | (84332) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total property, plant and equipment, net | $123818 | $127184 |

---

For the three months ended March 31, 2026, depreciation expense was $5.8 million. For the three months ended March 29, 2025, depreciation expense was $4.4 million.

**NOTE 7. Commitments and Contingencies**

*Warranty Reserves*

The Company generally provides a warranty on its products for a period of 12 to 14 months against defects in material and workmanship. The Company estimates the costs that may be incurred during the warranty period and records a liability in the amount of such costs at the time revenue is recognized. The Company's estimate is based primarily on historical experience. The Company periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary. Warranty provisions are generally related to current period sales. Settlements of warranty reserves are generally associated with sales that occurred during the 12 to 14 months prior to the period-end.

Changes in the Company's warranty reserves are as follows:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 29,** |
|  | **2026** | **2025** |
|  | **(in thousands)** | **(in thousands)** |
| Balance, beginning of the period | $10292 | $10858 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accruals | 2460 | 3773 |
| &nbsp;&nbsp;&nbsp;&nbsp;Usage | (3163) | (2639) |
| Balance, end of the period | $9589 | $11992 |

---

Warranty reserves are reported in the Condensed Consolidated Balance Sheets under the captions "Accrued liabilities" and "Other non-current liabilities."

------

[**<u>**Table of Contents**</u>**](#toc_page)

*Legal Matters*

From time to time, the Company is subject to legal proceedings and claims in the ordinary course of business. In the opinion of management, any potential liabilities resulting from any current disputes would not have a material adverse effect on the Company's unaudited interim condensed consolidated financial statements.

*Line of Credit*

The Company had a credit agreement with a bank that provided for a variable-rate line of credit secured by the marketable securities the Company had with the bank. At January 3, 2026 the Company was permitted to borrow up to 70.0% of the value of eligible securities held at the time the line of credit was accessed, up to a maximum of $100.0 million. The available line of credit as of January 3, 2026 was $100.0 million with an available interest rate of 4.3%. The Company terminated this line of credit during the three months ended March 31, 2026, and did not utilize the line of credit while it was active.

**NOTE 8. Revenue**

The following table represents a disaggregation of revenue by timing of revenue:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 29,** |
|  | **2026** | **2025** |
|  | **(in thousands)** | **(in thousands)** |
| Point-in-time | $271579 | $249279 |
| Over-time | 20370 | 17328 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total revenue | $291949 | $266607 |

---

The following table lists the different sources of revenue:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 31,** | **March 29,** | **March 29,** |
|  | **2026** | **2026** | **2025** | **2025** |
|  | **(in thousands, except for percentages)** | **(in thousands, except for percentages)** | **(in thousands, except for percentages)** | **(in thousands, except for percentages)** |
| Systems and software | $247157 | 84.7% | $231150 | 86.7% |
| Parts | 26550 | 9.1% | 18176 | 6.8% |
| Services | 18242 | 6.2% | 17281 | 6.5% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total revenue | $291949 | 100.0% | $266607 | 100.0% |

---

See Note 12 for additional discussion of the Company's disaggregated revenue by geography.

*Contract Assets and Contract Liabilities*

Contract assets consist of amounts we have not invoiced but have completed the related performance obligation. These amounts generally arise from variances between the contractual payment terms and the transaction price assigned to the open performance obligations (e.g., we have recognized revenue in an amount greater than the amount that is billable under the contract). The contract assets amounts are recorded in "Accounts receivable" in the Condensed Consolidated Balance Sheets. As of March 31, 2026 the Company had no contract assets, and as of January 3, 2026, the Company had contract assets of $3.5 million.

The Company records contract liabilities when the customer has been billed in advance of the Company completing its performance obligations primarily with respect to liabilities related to service contracts and installation. For contracts that have a duration of one year or less, these amounts are recorded as "Deferred revenue" in the Condensed Consolidated Balance Sheets. For contracts with a duration longer than one year, deferred revenue is recorded in "Other non-current liabilities" in the Condensed Consolidated Balance Sheets. As of March 31, 2026 and January 3, 2026, the Company carried a long-term deferred revenue balance of $8.3 million and $6.3 million, respectively, within "Other non-current liabilities" in the Condensed Consolidated Balance Sheets.

------

[**<u>**Table of Contents**</u>**](#toc_page)

Changes in deferred revenue were as follows:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 29,** |
|  | **2026** | **2025** |
|  | **(in thousands)** | **(in thousands)** |
| Balance, beginning of the period | $38031 | $37836 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferral of revenue | 16554 | 28982 |
| &nbsp;&nbsp;&nbsp;&nbsp;Recognition of current year deferred revenue | (1021) | (8987) |
| &nbsp;&nbsp;&nbsp;&nbsp;Recognition of prior period deferred revenue | (13831) | (14232) |
| Balance, end of the period | $39733 | $43599 |

---

**NOTE 9. Share-Based Compensation**

The following table presents the detail of share-based compensation expense amounts included in the Company's Condensed Consolidated Statement of Operations:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 29,** |
|  | **2026** | **2025** |
|  | **(in thousands)** | **(in thousands)** |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of revenue | $943 | $1107 |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | 1015 | 1062 |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales and marketing | 1029 | 1339 |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 4024 | 3306 |
| Total share-based compensation expense | $7011 | $6814 |

---

As of March 31, 2026, there was $49.1 million of total unrecognized compensation cost related to restricted stock units granted under the Company's stock plans. That cost is expected to be recognized over a weighted average period of 1.9 years following March 31, 2026.

**NOTE 10. Income Taxes**

During the three months ended March 31, 2026 and March 29, 2025, the Company recognized an income tax provision of $4.3 and $7.6 million, respectively, representing an effective tax rate of 11.3% and 10.6%, respectively.

The effective tax rate for the periods presented is less than the U.S. statutory rate primarily due to projected Foreign Derived Intangible Income deductions, federal research and development tax credits, and excess tax benefits associated with equity compensation.

**NOTE 11. Earnings Per Share**

Basic earnings per share is calculated using the weighted average number of shares of common stock outstanding during the period. Restricted stock units and employee stock purchase grants are included in the calculation of diluted earnings per share, except when their effect would be anti-dilutive. For the three months ended March 31, 2026 and March 29, 2025, 23 thousand and 19 thousand, respectively, restricted stock units were excluded from the computation of diluted earnings per share as their impact would have been antidilutive.

------

[**<u>**Table of Contents**</u>**](#toc_page)

The Company's basic and diluted earnings per share amounts are as follows:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 29,** |
|  | **2026** | **2025** |
|  | **(in thousands, except for per share data)** | **(in thousands, except for per share data)** |
| Numerator: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income | $33750 | $64095 |
| Denominator: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic earnings per share - weighted average shares outstanding | 49742 | 49180 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of potential dilutive securities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restricted stock units and employee stock purchase grants - dilutive shares | 262 | 228 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted earnings per share - weighted average shares outstanding | 50004 | 49408 |
| Earnings per share: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | $0.68 | $1.30 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | $0.67 | $1.30 |

---

**NOTE 12. Segment Reporting and Geographic Information**

The Company is organized and operates as one operating and reportable segment; the design, development, manufacture and support of high-performance control metrology, defect inspection, lithography and data analysis systems used by microelectronics device manufacturers. This determination is based on the management approach which designates internal information regularly available to the Chief Operating Decision Maker ("CODM") for making decisions and assessing performance as the source of determination of the Company's reportable segments. The Company's CODM, the Chief Executive Officer, reviews financial information presented on a consolidated basis for the purpose of making operating decisions and assessing financial performance. The CODM uses net income as the measure of profit or loss to allocate resources and assess performance. The measure of segment assets is reported on the balance sheet as total assets.

The table below presents the Company's consolidated operating results including significant segment expenses:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 29,** |
|  | **2026** | **2025** |
|  | **(in thousands)** | **(in thousands)** |
| Revenue | $291949 | $266607 |
| Less: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted cost of revenue <sup>(1)</sup> | 129225 | 119739 |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted research and development <sup>(2)</sup> | 35098 | 28720 |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted sales and marketing <sup>(2)</sup> | 21459 | 19716 |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted general and administrative <sup>(2)</sup> | 28294 | 21937 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other segment items: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring and other <sup>(3)</sup> | 15396 | 4758 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Merger and acquisitions related <sup>(3)</sup> | 9263 | 158 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization | 19700 | 8445 |
| Operating income | 33514 | 63134 |
| Total other income, net | 4538 | 8523 |
| Provision for income taxes | 4302 | 7562 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net income | $33750 | $64095 |
| <sup>(1)</sup> Excludes restructuring and other expenses and merger and acquisition related expenses | <sup>(1)</sup> Excludes restructuring and other expenses and merger and acquisition related expenses | <sup>(1)</sup> Excludes restructuring and other expenses and merger and acquisition related expenses |
| <sup>(2)</sup> Excludes merger and acquisition related expenses | <sup>(2)</sup> Excludes merger and acquisition related expenses | <sup>(2)</sup> Excludes merger and acquisition related expenses |
| <sup>(3)</sup> The Company excludes these expenses in order to provide better comparability between periods as they are not representative of the Company's ongoing operations. | <sup>(3)</sup> The Company excludes these expenses in order to provide better comparability between periods as they are not representative of the Company's ongoing operations. | <sup>(3)</sup> The Company excludes these expenses in order to provide better comparability between periods as they are not representative of the Company's ongoing operations. |

---

------

[**<u>**Table of Contents**</u>**](#toc_page)

The Company's significant operations outside the United States include sales, service and application offices in Asia and Europe. For geographical revenue reporting, revenue is attributed to the geographic location to which the product is shipped. Revenue by geographic region is as follows:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 29,** |
|  | **2026** | **2025** |
|  | **(in thousands)** | **(in thousands)** |
| Revenue from third parties: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Taiwan | $84962 | $102581 |
| &nbsp;&nbsp;&nbsp;&nbsp;South Korea | 69844 | 93314 |
| &nbsp;&nbsp;&nbsp;&nbsp;United States | 59241 | 25597 |
| &nbsp;&nbsp;&nbsp;&nbsp;China | 27778 | 12176 |
| &nbsp;&nbsp;&nbsp;&nbsp;Japan | 16876 | 8369 |
| &nbsp;&nbsp;&nbsp;&nbsp;Southeast Asia | 16697 | 8026 |
| &nbsp;&nbsp;&nbsp;&nbsp;Europe | 16551 | 16544 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total revenue | $291949 | $266607 |

---

The following customers accounted for 10.0% or more of total revenue for the indicated periods:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 29,** |
|  | **2026** | **2025** |
| Customer A | 14.4% | 14.4% |
| Customer B | 13.4% | ^ |
| Customer C | 13.3% | 24.0% |
| Customer D | ^ | 21.1% |
| ^ The customer accounted for less than 10.0% of total revenue during the period. |  |  |

---

Two customers' accounts receivable balances were individually greater than 10.0% of net accounts receivable at March 31, 2026, representing, in the aggregate approximately 27.0% of the Company's total accounts receivable.

One customer's accounts receivable balances was individually greater than 10.0% of net accounts receivable at January 3, 2026, representing, approximately 12.2% of the Company's total accounts receivable.

Substantially all of the Company's long-lived assets are located within the United States of America.

**NOTE 13. Share Repurchase Authorization**

In February 2024, the Onto Innovation Board of Directors approved a share repurchase authorization, which allows the Company to repurchase up to $200 million worth of shares of its common stock. Repurchases may be made through both public market and private transactions from time to time. Any amount paid to repurchase the shares in excess of par value, including transaction costs, would be recorded directly as a decrease to additional paid-in capital and accumulated earnings. During the three months ended March 31, 2026, no shares of the Company's common stock were repurchased under the share repurchase authorization. During the three months ended March 29, 2025, 492 thousand shares of the Company's common stock were repurchased under the share repurchase authorization. At March 31, 2026, there was $99.9 million available for future share repurchases under this share repurchase authorization.

**NOTE 14. Restructuring and Other**

From time to time, the Company approves restructuring plans, which include workforce reductions, to streamline operations and align the Company's cost structure with its business outlook. These restructuring plans may result in charges to cost of goods sold for streamlining of certain manufacturing activities and other charges, including inventory write-downs primarily related to the exit of older product lines. Charges to operating expenses primarily include employee severance costs

------

[**<u>**Table of Contents**</u>**](#toc_page)

that are paid during the period incurred, charges for streamlining of certain operating activities and impairment charges such as plant, property and equipment.

Restructuring and other expenses recorded in the Condensed Consolidated Statements of Operations are as follows:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 29,** |
|  | **2026** | **2025** |
|  | **(in thousands)** | **(in thousands)** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cost of goods sold | $10187 | $3635 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating expenses | 5209 | 1123 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total restructuring and other | $15396 | $4758 |

---

**NOTE 15. Subsequent Event**

On April 20, 2026, the Company entered into a definitive share purchase agreement ("the Transaction") with Atom Investment, L.P., an affiliate of The Carlyle Group, to acquire 27% of the outstanding common stock of Rigaku Holdings Corporation ("Rigaku") for approximately $710 million. In connection with the Transaction, Onto Innovation Inc. will receive the right to nominate one director to Rigaku's board. The Company expects to account for the minority investment under the fair value option method and will not consolidate financial results. The transaction is expected to close in the second half of 2026.

Also on April 20, 2026, the Company entered into a commitment letter with Goldman Sachs Bank USA, which provides for a senior secured 364-day $500 million bridge term loan credit facility. The bridge term loan is intended to be available to the Company to finance, together with other sources of funds, the Transaction and related fees and expenses on or prior to the closing of the Transaction.

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations** 

**Forward-Looking Statements**

Certain statements in this Form 10-Q, or incorporated by reference in this Form 10-Q, of Onto Innovation Inc. (referred to in this Form 10-Q, together with its consolidated subsidiaries, unless otherwise specified or suggested by the context, as the "Company," "Onto Innovation," "we," "our" or "us") are considered "forward-looking statements" or are based on "forward-looking statements," including, but not limited to, those concerning:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our business momentum and future growth;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•technology development, product introduction and acceptance of our products and services;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our manufacturing practices and ability to deliver both products and services consistent with our customers' demands and expectations and to strengthen our market position, including our ability to source components, materials, and equipment due to supply chain delays or shortages;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the integration of Semilab USA LLC ("Semilab USA");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our expectations of the semiconductor market outlook;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•future revenue, gross profits, research and development and engineering expenses, selling, general and administrative expenses, and cash requirements;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the anticipated effects of tariffs and trade disputes on our business and financial results;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the effects of natural disasters or public health emergencies on the global economy and on our customers, suppliers, employees, and business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our dependence on certain significant customers and anticipated trends and developments in and management plans for our business and the markets in which we operate; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to be successful in managing our cost structure and cash expenditures and results of litigation.

------

[**<u>**Table of Contents**</u>**](#toc_page)

Statements contained or incorporated by reference in this Form 10-Q that are not purely historical are forward-looking statements and are subject to safe harbors under Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as, but not limited to, "anticipate," "believe," "continue," "estimate," "expect," "intend," "plan," "should," "may," "could," "will," "would," "forecast," "project" and words or phrases of similar meaning, as they relate to our management or us.

Forward-looking statements contained herein reflect our current expectations, assumptions and projections with respect to future events and are subject to certain risks, uncertainties and assumptions. Actual results may differ materially and adversely from those included in such forward-looking statements as a result of various factors, including risks and uncertainties, many of which are beyond Onto Innovation's control. Such factors include, but are not limited to, the Company's ability to leverage its resources to improve its position in its core markets; its ability to weather difficult economic environments; its ability to open new market opportunities and target high-margin markets; the strength/weakness of the back-end and/or front-end semiconductor market segments; fluctuations in customer capital spending; the Company's ability to effectively manage its supply chain and adequately source components from suppliers to meet customer demand; the effects of political, economic, legal, and regulatory changes or uncertainties, changes in U.S. tariff and trade policy and related retaliatory actions, and geopolitical conflicts, including the ongoing conflict involving Israel, the U.S., Iran and other actors, on the Company's global operations; the Company's ability to adequately protect its intellectual property rights and maintain data security; the effects of natural disasters or public health emergencies on the global economy and on the Company's customers, suppliers, employees, and business; its ability to effectively maneuver global trade issues and changes in trade and export regulations, tariffs and license policies; the Company's ability to maintain relationships with its customers and manage appropriate levels of inventory to meet customer demands; the Company's ability to realize the anticipated benefits of the proposed investment in and strategic partnership with Rigaku; the Company's ability to complete the proposed transaction on the timing expected or at all; the ability to obtain required regulatory approvals for the proposed transaction on the timing expected or at all; the availability of debt financing for the transaction; the Company's timing and ability to repay its debt; and the Company's ability to successfully integrate acquired businesses and technologies, including the business of Semilab USA and to realize the anticipated benefits of such acquisitions. Additional information and considerations regarding the risks faced by Onto Innovation are available in our Annual Report on Form 10-K for the fiscal year ended January 3, 2026 (the "2025 Form 10-K") filed with the Securities and Exchange Commission (the "SEC") on February 24, 2026, in Part II, Item 1A. "Risk Factors" and elsewhere in this Form 10-Q, and in the other filings that we make with the SEC from time to time. Forward-looking statements reflect our position as of the date of this Form 10-Q and we undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

**Critical Accounting Estimates**

The preparation of condensed consolidated financial statements and related disclosures in conformity with accounting principles generally accepted in the United States ("U.S. GAAP") requires management to make judgments, assumptions and estimates that affect the amounts reported.

Estimates and assumptions about future events and their effects cannot be determined with certainty. We base our estimates on historical experience and on various other assumptions believed to be applicable and reasonable under the circumstances. These estimates may change as new events occur, as additional information is obtained and as our operating environment changes. In addition, management is periodically faced with uncertainties, the outcomes of which are not within our control and will not be known for prolonged periods of time. Certain of these uncertainties are discussed in the 2025 Form 10-K in the Items entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations." There have been no material changes in our critical accounting estimates from the information presented in Part II, Item 7. "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the 2025 Form 10-K.

For more information, please see our critical accounting estimates as previously disclosed in the 2025 Form 10-K and recent accounting pronouncements discussed in Note 1 to the Condensed Consolidated Financial Statements.

**Executive Summary**

We are a worldwide leader in the design, development, manufacture and support of process control tools that perform macro-defect inspection and metrology, lithography systems, and process control analytical software used by semiconductor and advanced packaging device manufacturers. We deliver comprehensive solutions throughout the semiconductor fabrication process with our families of proprietary products that provide critical yield-enhancing information, enabling microelectronic device manufacturers to drive down costs and time to market of their devices. We provide process and yield management solutions

------

[**<u>**Table of Contents**</u>**](#toc_page)

used in both wafer processing facilities, often referred to as "front-end" manufacturing, and in device packaging and test facilities, commonly referred to as "back-end" manufacturing. Our advanced process control software portfolio includes powerful solutions for standalone tools, groups of tools, or factory-wide suites to enhance productivity and achieve significant cost savings.

Our principal market is semiconductor capital equipment. Semiconductors packaged as ICs, or "chips," are used in consumer electronics, server and enterprise systems, mobile computing (including smart phones and tablets), data storage devices, and embedded automotive and control systems. Our core focus is the measurement and control of the structure, composition, and geometry of semiconductor devices as they are fabricated on silicon wafers to improve device performance and manufacturing yields.

Our products and services are used by our customers who manufacture many types of ICs for a multitude of applications, each having unique manufacturing challenges. This includes ICs to enable information processing and management (logic ICs), memory storage (NAND, 3D-NAND, NOR, and DRAM), analog devices (e.g., Wi-Fi and 5G radio ICs, power devices), MEMS sensor devices (accelerometers, pressure sensors, microphones), image sensors, and other end markets including components for AI, hard disk drives, LEDs, and power management.

The semiconductor and electronics industries have also been characterized by constant technological innovation. We believe that, over the long term, our customers will continue to invest in advanced technologies and new materials to enable smaller design rules and higher density applications that fuel demand for process control equipment.

The following table summarizes certain key financial information for the periods indicated below:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,<br>2026** | **January 3,<br>2026** |
|  | **(in thousands, except for percentages and per share data)** | **(in thousands, except for percentages and per share data)** |
| Revenue | $291949 | $266866 |
| Gross profit | $146389 | $123792 |
| Gross profit as a percentage of revenue | 50.1% | 46.4% |
| Total operating expenses | $112875 | $109934 |
| Net income | $33750 | $10529 |
| Diluted earnings per share | $0.67 | $0.21 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•In the fiscal quarter ended March 31, 2026 (the "March 2026 quarter"), revenue increased 9.4% compared to the fiscal quarter ended January 3, 2026 (the "January 2026 quarter"), primarily due to revenue attributed to the acquired Semilab USA business of $16.8 million and higher sales to logic and memory customers in advanced nodes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Gross profit as a percentage of revenue for the March 2026 quarter increased by 3.7% compared to the January 2026 quarter. This margin increase was primarily driven by reductions in inventory write downs, restructuring costs related to infrastructure transition, and reductions in costs related to contract manufacturing set-up. In addition, during the March 2026 quarter $2.2 million of additional inventory step-up amortization was recognized compared to the January 2026 quarter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Operating expenses for the March 2026 quarter increased by 2.7% compared to the January 2026 quarter. This increase was driven by an increase in intangible amortization expense, offset by reductions in transaction costs related to the acquisition of Semilab USA.

Our cash, cash equivalents and marketable securities balance increased to $654.2 million at March 31, 2026, compared to $639.6 million at January 3, 2026. This increase was primarily the result of $26.3 million of cash generated from operating activities partially offset by capital expenditures of $3.6 million and $6.7 million for tax payments related to net share settlement of employee stock-based compensation plans. Employee headcount at March 31, 2026 was approximately 1,790.

On April 20, 2026, we entered into a definitive share purchase agreement (the "Transaction") with Atom Investment, L.P., an affiliate of The Carlyle Group, to acquire 27% of the outstanding common stock of Rigaku Holdings Corporation ("Rigaku") for approximately $710 million. The Transaction is expected to close in the second half of 2026. Also on April 20, 2026, we entered into a commitment letter with Goldman Sachs Bank USA, which provides for a senior secured 364-day $500 million bridge term loan credit facility. The bridge term loan is intended to be available to the Company to finance, together with other sources of funds, the Transaction and related fees and expenses on or prior to the closing of the Transaction.

------

[**<u>**Table of Contents**</u>**](#toc_page)

For a discussion of the risks related to our business and operations, see Part I, Item 1A - Risk Factors of the 2025 Form 10-K and Part II, Item 1A - Risk Factors of this Form 10-Q.

**Results of Operations for the Three-Months ended March 31, 2026 and March 29, 2025** 

*Revenue.* Our revenue is primarily derived from the sale of our systems, software licensing, services and spare parts. Our revenue of $291.9 million increased 9.5% for the three months ended March 31, 2026 as compared to the three months ended March 29, 2025, for which revenue totaled $266.6 million.

The following table lists, for the periods indicated, the different sources of our revenue in dollars and as percentages of our total revenue:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 31,** | **March 29,** | **March 29,** |
|  | **2026** | **2026** | **2025** | **2025** |
|  | **(in thousands, except for percentages)** | **(in thousands, except for percentages)** | **(in thousands, except for percentages)** | **(in thousands, except for percentages)** |
| Systems and software | $247157 | 84.7% | $231150 | 86.7% |
| Parts | 26550 | 9.1% | 18176 | 6.8% |
| Services | 18242 | 6.2% | 17281 | 6.5% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total revenue | $291949 | 100.0% | $266607 | 100.0% |

---

Total systems and software revenue increased $16.0 million for the three months ended March 31, 2026, as compared to the three months ended March 29, 2025. The increase was attributable to Semilab USA revenues of $24.0 million, as well as higher sales to advanced packaging customers, partially offset by a decline in sales to advanced node customers. The increase in total parts and services revenue for the three months ended March 31, 2026, as compared to the three months ended March 29, 2025, was primarily due to increased spending by our customers on system upgrades and repairs of existing systems.

*Gross Profit.* Our gross profit has been and will likely continue to be affected by a variety of factors, including manufacturing efficiencies, provision for excess and obsolete inventory, pricing by competitors or suppliers, new product introductions, production volume, customization and reconfiguration of systems, international and domestic sales mix, system and software product mix and parts and service margins.

The following table lists, for the periods indicated, our gross profit in dollars and as percentages of our total revenue:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 29,** |
|  | **2026** | **2025** |
|  | **(in thousands, except for percentages)** | **(in thousands, except for percentages)** |
| Gross profit | $146389 | $143233 |
| Gross profit as a percentage of revenue | 50.1% | 53.7% |

---

The decrease in gross profit as a percentage of revenue for the three months ended March 31, 2026 as compared to the three months ended March 29, 2025 was primarily due to higher restructuring and other expenses for the write down of excess and obsolete inventory in the 2026 period. In addition, $6.1 million of inventory step-up amortization attributed to Semilab USA was recognized during the three months ended March 31, 2026.

*Operating Expenses.* 

Our operating expenses consist of:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•*<u>Research and Development</u>.* We believe that it is critical to continue to make substantial investments in research and development to ensure the availability of innovative technology that meets the current and projected requirements of our customers' most advanced designs. We have maintained and intend to continue our commitment to investing in research and development in order to continue to offer new products and technologies. Accordingly, we devote a significant portion of our technical, management and financial resources to research and development programs. Research and development expenditures consist primarily of salaries and related expenses of employees engaged in research, design and development activities. These expenditures also include consulting fees, the cost of related supplies and legal costs to defend our patents. Our research and development expenses were $35.1 million for the

------

[**<u>**Table of Contents**</u>**](#toc_page)

three-month period ended March 31, 2026, as compared to $28.0 million for the three-month period ended March 29, 2025. The increase in research and development expenses for the three-month period ended March 31, 2026, as compared to the three-month period ended March 29, 2025 was primarily due to increases in headcount, as well as increased materials and supplies expensed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•*<u>Sales and Marketing</u>.* Sales and marketing expenses are primarily comprised of salaries, commissions and related costs for sales and marketing personnel, as well as other non-personnel related expenses. Our sales and marketing expenses were $21.5 million for the three-month period ended March 31, 2026, compared to $19.7 million for the three-month period ended March 29, 2025. The increase in sales and marketing expenses for the three-month period ended March 31, 2026, as compared to the three-month period ended March 29, 2025, was primarily driven by increases in headcount.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•*<u>General and Administrative</u>.* General and administrative expenses are primarily comprised of salaries and related costs for corporate and administrative personnel, as well as other non-personnel related expenses. Our general and administrative expenses were $31.4 million for the three-month period ended March 31, 2026, as compared to $22.8 million for the three-month period ended March 29, 2025. The increase in general and administrative expenses for the three-month period ended March 31, 2026, as compared to the three-month period ended March 29, 2025, was primarily driven by higher headcount-related compensation costs, expenses associated with the Semilab USA integration, ERP integration costs, related outside services and fees and other general corporate expenses.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•*<u>Amortization of Identifiable Intangible Assets</u>.* Amortization of identifiable intangible assets was $19.7 million for the three-month period ended March 31, 2026, compared to $8.4 million for the three-month period ended March 29, 2025. The increase in amortization of identifiable intangible assets for the three months ended March 31, 2026, as compared to the three months ended March 29, 2025, was due to recognition of a full quarter of Semilab USA amortization in the 2026 period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•*<u>Restructuring and Other</u>*<u>.</u> Restructuring and other expenses were $5.2 million for the three-month period ended March 31, 2026, compared to $1.1 million for the three-month period ended March 29, 2025. The increase in restructuring and other expenses for the three-month period ended March 31, 2026, as compared to the three-month period ended March 29, 2025, was primarily due to an increase in employee severance costs and business transformation projects that includes the streamlining of various operating activities.

*Total other income, net*. Total other income, net was $4.5 million for the three-month period ended March 31, 2026, as compared to $8.5 million for the three-month period ended March 29, 2025. The decrease in total other income, net for the three months ended March 31, 2026, as compared to the three months ended March 29, 2025, was attributable to interest on lower cash and marketable securities balances in the 2026 period following the use of cash for the acquisition of Semilab USA in the fourth quarter of 2025, partially offset by lower foreign currency exchange losses recognized in the 2026 period.

*Income Taxes*. We recorded an income tax provision of $4.3 million for the three-month period ended March 31, 2026, as compared to $7.6 million for the three-month period ended March 29, 2025. Our effective tax rate of 11.3% and 10.6% for the three-month period ended March 31, 2026 and the three-month period ended March 29, 2025, respectively, differed from the statutory rate of 21.0%, primarily due to the tax benefit associated with the Foreign Derived Intangible Income ("FDII") deductions, federal research and development tax credits, and excess tax benefits associated with equity compensation.

Our future effective income tax rate depends on various factors, such as possible changes in tax legislation, the geographic composition of our pre-tax income, the amount of our pre-tax income as business activities fluctuate, non-deductible expenses incurred in connection with business combinations, and research and development tax credits as a percentage of aggregate pre-tax income.

We currently have a partial valuation allowance recorded for certain foreign and state loss and credit carryforwards where the realizability of such deferred tax assets is substantially in doubt. Each quarter we assess the likelihood that we will be able to recover our deferred tax assets primarily relating to state research and development credits. We consider available evidence, both positive and negative, including historical levels of income, expectations and risks associated with estimates of future taxable income and ongoing prudent and feasible tax planning strategies in assessing the need for a valuation allowance. As a result of our analysis, we concluded that it is more likely than not that a portion of our net deferred tax assets will not be realized. Therefore, we continue to provide a valuation allowance against certain net deferred tax assets. We continue to monitor available evidence and may reverse some or all of the valuation allowance in future periods, if appropriate.

------

[**<u>**Table of Contents**</u>**](#toc_page)

The Organization for Economic Co-operation and Development ("OECD") has released guidance covering various topics, including country-by-country reporting, definitional changes to permanent establishment and Base Erosion and Profit Shifting ("BEPS"), an initiative that aims to standardize and modernize global tax policy. The guidance also established a global minimum tax of 15%. This guidance has been implemented by several jurisdictions, including jurisdictions in which we operate, and many other jurisdictions are in the process of implementing it. Depending on the final form of legislation ultimately enacted, there may be significant consequences for us due to our international business activities, including, but not limited to, an increase in our tax uncertainty and adverse effects on our provision for income taxes. On January 5, 2026, the OECD announced that the Inclusive Framework on Base Erosion and Profit Shifting agreed to a new package of administrative guidance under the Pillar Two global minimum tax rules. The new administrative guidance allows for U.S. multinationals to provide for a Side-by-Side Safe Harbor that would exclude U.S.-parented multinational groups from the global minimum tax rule's Income Inclusion Rule and Undertaxed Profits Rule on the grounds that the existing U.S. law is sufficiently robust in its taxation of domestic and foreign profits. Although we will continue to monitor U.S. and international legislative developments in this area, we cannot predict whether such protective measures or legislation will be adopted by non-U.S. countries, if any, and whether the U.S. would have any responsive measures.

On July 4, 2025, the United States enacted tax reform legislation through the One Big Beautiful Bill Act. Included in this legislation are provisions that allow for the immediate expensing of domestic U.S. research and development expenses, immediate expensing of certain capital expenditures, and other changes to the U.S. taxation of profits derived from foreign operations. The impact of the Act has been accounted for in the provision for taxes for the quarter ended March 31, 2026.

**Liquidity and Capital Resources**

Our cash, cash equivalents and marketable securities consist of the following in dollars for the periods indicated:

---

| | | |
|:---|:---|:---|
|  | **March 31,<br>2026** | **January 3,<br>2026** |
|  | **(in thousands)** | **(in thousands)** |
| Cash and cash equivalents | $252247 | $346119 |
| Marketable securities | 401917 | 293503 |
| &nbsp;&nbsp;Total cash, cash equivalents and marketable securities | $654164 | $639622 |

---

***Sources and Uses of Cash***

A summary of net cash and cash equivalents provided by (used in) operating, investing, and financing activities is as follows in dollars for the periods indicated:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 29,** |
|  | **2026** | **2025** |
|  | **(in thousands)** | **(in thousands)** |
| Net cash and cash equivalents provided by operating activities | $26322 | $91980 |
| Net cash and cash equivalents used in investing activities | $(112606) | $(21804) |
| Net cash and cash equivalents used in financing activities | $(6701) | $(79520) |

---

***Operating Activities***

Net cash and cash equivalents provided by operating activities for the three months ended March 31, 2026 was $26.3 million. The net cash and cash equivalents provided by operating activities during the three months ended March 31, 2026 resulted primarily from net income, adjusted to exclude the effect of non-cash operating charges, of $67.9 million. Significant non-cash operating charges included depreciation, amortization, share-based compensation and provision for inventory valuation. Cash provided by operating activities for the first three months of 2026 decreased compared to the corresponding period in fiscal 2025, primarily due to timing of accounts receivable payments and higher inventory levels due to revenue growth.

***Investing Activities***

Net cash and cash equivalents used in investing activities for the three months ended March 31, 2026 was $112.6 million. During the three months ended March 31, 2026, net cash and cash equivalents used in investing activities included purchases of

------

[**<u>**Table of Contents**</u>**](#toc_page)

marketable securities of $179.5 million and capital expenditures of $3.6 million, partially offset by proceeds from maturities and sales of marketable securities of $70.5 million.

From time to time, we evaluate whether to acquire new or complementary businesses, products or technologies. We may fund all of or a portion of the price of these investments or acquisitions in cash, stock, or a combination of cash and stock.

***Financing Activities***

Net cash and cash equivalents used in financing activities for the three months ended March 31, 2026 was $6.7 million. During the three months ended March 31, 2026, financing activities used cash for tax payments related to shares withheld to satisfy employee tax obligations in connection with the vesting of awards under share-based compensation plans.

In February 2024, our Board of Directors approved a share repurchase authorization, which allows the Company to repurchase up to $200 million worth of shares of its common stock. Repurchases may be made through both public market and private transactions from time to time. During the three months ended March 31, 2026, the Company repurchased no shares of common stock under this repurchase authorization. As of March 31, 2026, there was $99.9 million available for future share repurchases under this share repurchase authorization.

The Company had a credit agreement with a bank that provides for a variable-rate line of credit which was secured by the marketable securities the Company has with the bank. At January 3, 2026 the Company was permitted to borrow up to 70.0% of the value of eligible securities held at the time the line of credit would be accessed, up to a maximum of $100.0 million. The available line of credit as of January 3, 2026 was $100.0 million with an available interest rate of 4.3%. The Company terminated this line of credit during the three months ended March 31, 2026, and did not utilize the line of credit while it was active.

Our future capital requirements will depend on many factors, including the timing and amount of our revenue and our investment decisions, which will affect our ability to generate additional cash. We expect that our existing cash, cash equivalents and marketable securities will be sufficient to meet our anticipated cash requirements for working capital, capital expenditures, and other cash needs for the next 12 months following the filing of this Form 10-Q. Thereafter, if cash generated from operations and financing activities is insufficient to satisfy our working capital requirements, we may seek additional funding through bank borrowings, sales of securities or other means. A reduction in or volatility with respect to our stock price or a general market downturn could materially impact our ability to sell securities on favorable terms or at all. There can be no assurance that we will be able to raise any such capital on terms acceptable to us or at all.

**Item 3. Quantitative and Qualitati** **ve Disclosures About Market Risk**

There have been no material changes in market risk from the information presented in Part II, Item 7A. "Quantitative and Qualitative Disclosures About Market Risk," in the 2025 Form 10-K.

**Item 4. Controls and Procedures**

**Evaluation of Disclosure Controls and Procedures**

We maintain disclosure controls and procedures that are designed to ensure that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time period specified in SEC rules and forms. These controls and procedures are also designed to ensure that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating disclosure controls and procedures, we have recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Management is required to apply judgment in evaluating its controls and procedures.

We performed an evaluation under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, to assess the effectiveness of the design and operation of our disclosure controls and procedures under the Exchange Act as of March 31, 2026. Based on that evaluation, our management, including our principal executive officer and principal financial officer, concluded that our disclosure controls and procedures were effective as of March 31, 2026 at the reasonable assurance level.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**Changes in Internal Control over Financial Reporting**

There have been no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that occurred during our fiscal quarter ended March 31, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

**PART II OTHER** **INFORMATION**

**Item 1. Legal Proceedings**

For a description of our material pending legal proceedings refer to the information set forth under "Legal Matters" of Note 7, "Commitments and Contingencies," to the Condensed Consolidated Financial Statements included in Part 1, Item 1 of this Form 10-Q.

**Item 1A. Risk Factors.**

There have been no material changes from the risk factors previously disclosed under the heading "Risk Factors" in the 2025 Form 10-K, except as set forth below. We may disclose additional changes to risk factors or additional factors from time to time in our future filings with the SEC.

Our ability to complete our acquisition of Rigaku shares is subject to various closing conditions, including the receipt of consents and approvals from governmental authorities, which may impose conditions that could adversely affect us or cause the transaction not to be completed; and if we are able to complete the transaction, we may be unable to realize the anticipated benefits.

On April 20, 2026, we entered into a share purchase agreement (the Purchase Agreement) to acquire 27% of the outstanding common stock of Rigaku from Atom Investments, L.P., an affiliate of The Carlyle Group (Carlyle). The acquisition is subject to customary closing conditions, including certain regulatory approvals, as specified in the Purchase Agreement. No assurance can be given that the required conditions to closing will be satisfied, and, even if all required approvals are obtained and the required conditions are satisfied, no assurance can be given as to the terms, conditions and timing of such approvals. Any delay in completing the acquisition could cause the company not to realize, or to be delayed in realizing, some or all of the benefits that we expect to achieve if the acquisition is successfully completed within its expected time frame. Even if the transaction closes timely, we also cannot be sure that we will recognize the anticipated benefits of the transaction. As a minority shareholder in Rigaku, we will not be able to direct Rigaku's management or cause dividends or distributions to be made to us. The value of our Rigaku shares could also decline for a number of reasons, including reasons that are outside of our control, which could adversely affect our financial position. Our Rigaku shares are also subject to certain restrictions on transfer, which could make it difficult for us to sell our shares. If we are unable to successfully maximize the benefits of our investment in and collaboration with Rigaku, our business, financial condition and operating results could be adversely affected.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

In February 2024, the Onto Innovation Board of Directors approved a new share repurchase authorization, which allows the Company to repurchase up to $200 million worth of shares of its common stock. There were no shares of common stock repurchased under this authorization during the three months ended March 31, 2026. There was $99.9 million available for future share repurchases under this share repurchase authorization at March 31, 2026. For further information, see Note 13, "Share Repurchase Authorization," of the Notes to the Condensed Consolidated Financial Statements.

In addition to our share repurchase program, we withhold common stock shares associated with net share settlements to cover tax withholding obligations upon the vesting of restricted stock unit awards under the Company's equity incentive program.

------

[**<u>**Table of Contents**</u>**](#toc_page)

The following table provides details of common stock purchased during the three months ended March 31, 2026 (in thousands, except per share data):

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Period** | **Total Number <br>of Shares <br>Purchased** | **Average Price Paid per Share** | **Total Number of Shares Purchased as Part of Publicly Announced Program** | **Maximum Approximate Dollar Value of Shares that May Yet be Purchased Under the Program** |
|  | **(in thousands, except for per share data)** | **(in thousands, except for per share data)** | **(in thousands, except for per share data)** | **(in thousands, except for per share data)** |
| Jan 4, 2026 to Jan 31, 2026 |  | $— |  | $99935 |
| Feb 1, 2026 to Feb 28, 2026 | 17 | $217.23 |  | $99935 |
| Mar 1, 2026 to Mar 31, 2026 | 14 | $211.69 |  | $99935 |
| &nbsp;&nbsp;&nbsp;&nbsp;Three months ended March 31, 2026 | 31 | $214.78 |  |  |

---

**Item 3. Defaults Upon Senior Securities**

None.

**Item 4. Mine Safety Disclosures**

None.

**Item 5. Other Information**

Rule 10b5-1 Plan Elections

During the fiscal quarter ended March 31, 2026, the following officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement" (as those terms are defined in Item 408 of Regulation S-K), as follows:

On February 24, 2026, Yoon Ah E. Oh, the Company's Senior Vice President, General Counsel and Corporate Secretary, adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 10,278 shares of our common stock. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is until February 24, 2027, or earlier if all transactions under the trading arrangement are completed.

On February 25, 2026, Ido Dolev, the Company's Executive Vice President, Product Solutions Group, adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 100.0% of the shares of our common stock issued upon the settlement of 7,187 outstanding RSUs, less the number of shares traded to cover tax withholding obligations in connection with the vesting and settlement of such RSUs. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is until February 24, 2027, or earlier if all transactions under the trading arrangement are completed.

On March 9, 2026, Michael P. Plisinski, the Company's Chief Executive Officer, adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 65,937 shares of our common stock. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is until January 31, 2027, or earlier if all transactions under the trading arrangement are completed.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**Item 6. Exhibits**

---

| | |
|:---|:---|
| **<u>Exhibit No.</u>** | **<u>Description</u>** |
| [<u>2.1^</u>](https://www.sec.gov/Archives/edgar/data/0000704532/000119312526164529/d75499dex21.htm) | [<u>Share Purchase Agreement, dated as of April 21, 2026 (Tokyo time), by and between Onto Innovation Inc. and Atom Investments, L.P, incorporated by reference to Exhibit 2.1 to the Company's Form 8-K filed with the SEC on April 21, 2026 (File No. 001-39110).</u>](https://www.sec.gov/Archives/edgar/data/0000704532/000119312526164529/d75499dex21.htm) |
| [<u>3.1</u>](https://www.sec.gov/Archives/edgar/data/0000704532/000119312519275593/d823487dex32.htm) | [<u>Amended and Restated Certificate of Incorporation of Onto Innovation Inc., dated October 25, 2019, incorporated by reference to Exhibit 3.2 to the Company's Form 8-K filed with the SEC on October 28, 2019 (File No. 001-39110).</u>](https://www.sec.gov/Archives/edgar/data/0000704532/000119312519275593/d823487dex32.htm) |
| [<u>3.2</u>](https://www.sec.gov/Archives/edgar/data/0000704532/000156459020001927/onto-ex31_41.htm) | [<u>Amended and Restated Bylaws of Onto Innovation Inc., dated January 22, 2020, incorporated by reference to Exhibit 3.1 to the Company's Form 8-K filed with the SEC on January 27, 2020 (File No. 001-39110).</u>](https://www.sec.gov/Archives/edgar/data/0000704532/000156459020001927/onto-ex31_41.htm) |
| [<u>10.1\*+</u>](onto-ex10_1.htm) | [<u>Offer Letter to Ido Dolev, dated October 30, 2024, by and between Ido Dolev and Onto Innovation Inc.</u>](onto-ex10_1.htm) |
| [<u>10.2\*+</u>](onto-ex10_2.htm) | [<u>Offer Letter to Shirley Chen, dated May 16, 2025, by and between Shirley Chen and Onto Innovation Inc.</u>](onto-ex10_2.htm) |
| [<u>31.1\*</u>](onto-ex31_1.htm) | [<u>Rule 13a-14(a) Certification of Chief Executive Officer of the Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>](onto-ex31_1.htm) |
| [<u>31.2\*</u>](onto-ex31_2.htm) | [<u>Rule 13a-14(a) Certification of Chief Financial Officer of the Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>](onto-ex31_2.htm) |
| [<u>32.1\*\*</u>](onto-ex32_1.htm) | [<u>Certification of the Chief Executive Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>](onto-ex32_1.htm) |
| [<u>32.2\*\*</u>](onto-ex32_2.htm) | [<u>Certification of the Chief Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>](onto-ex32_2.htm) |
| 101.INS\* | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
| 101.SCH\* | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents |
| 104\* | Cover Page Interactive Data File (formatted as Inline XBRL and included in Exhibit 101) |

---

------

\* Filed herewith.

\*\* Furnished herewith.

+ Management contract, compensatory plan or arrangement.

^ Schedules omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request.

------

[**<u>**Table of Contents**</u>**](#toc_page)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  | **Onto Innovation Inc.** | **Onto Innovation Inc.** |
| Date: | May 5, 2026 | By: | /s/ Michael P. Plisinski |
|  |  | Michael P. Plisinski | Michael P. Plisinski |
|  |  | Chief Executive Officer | Chief Executive Officer |
| Date: | May 5, 2026 | By: | /s/ Brian K. Roberts |
|  |  | Brian K. Roberts | Brian K. Roberts |
|  |  | Chief Financial Officer and Principal Accounting Officer | Chief Financial Officer and Principal Accounting Officer |

---

------

## Exhibit 10.1

Exhibit 10.1

October 30, 2024 Dear Ido,

I am pleased to offer you the position of Executive Vice President, Process Control Group on a Regular, Full-time basis, reporting to me (Mike Plisinski) in our Wilmington, MA location. Your start date is projected to be December 1<sup>st</sup> , 2024; however, it may be later as it is subject to the conditions set forth herein.

Your total rewards package includes the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Your starting salary will be **$17,307.69** per pay period subject to required withholding and deductions, which when annualized is **$450,000.00**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•You will be eligible to participate in the Company's Key Executive Incentive Compensation Plan with a cash bonus target of **70%** of your base salary, the terms of which will be approved by the Compensation Committee of the Board of Directors. Eligibility will begin in the 2025 plan year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•As a senior executive your participation in the Key Executive Incentive Compensation Plan includes an annual equity grant. These grants are typically made in the February timeframe and though not guaranteed, we'd expect a grant with a value of approximately **$800,000.00** will be extended to you, subject to the annual approval of the Compensation Committee. These grants are awarded as follows: 50% are time-based, vesting in equal installments over 3 years, and 50% are performance based, contingent on Onto Innovation's stock performance as compared with the SOXX index as of the 2- and 3-year anniversaries of the grant date. All annual grants are subject to the terms of the Onto Innovation 2020 Stock Plan. You will be eligible for your first equity grant in FY 2025

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•We will provide relocation support to assist in your family's transition from Israel to the Massachusetts area. We ask that your move be completed by July 1, 2025. Executive relocation assistance is provided by our approved relocation vendor (Plus-Relocation) up to a maximum value of **$100,000.00** (this amount will be eligible for a flat supplemental gross-up). Program details, and our executive relocation agreement will be provided separately for your review and signature.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Onto will provide immigration assistance for yourself and your family. This includes the financial and legal support required to process entry and settlement visas, and permanent residence (if requested).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Executive benefits also include:

oReimbursement for tax preparation services

oNorton/LifeLock advanced executive privacy support

oAn annual airline club membership

Onto Innovation, Inc. has an excellent benefits program including Health, Dental, Vision, Life and Short and Long-Term Disability insurance coverage. Onto Innovation, Inc. will pay a portion of the cost of your insurance coverage and a portion of your dependents' coverage in accordance with the terms of the applicable benefit plans. Onto Innovation, Inc. may modify benefits from time to time at its sole discretion.

This offer is a result of your individual skills and talent and not for any trade secrets or proprietary information, you may have gained elsewhere. Please do not bring any confidential materials belonging to third parties to Onto Innovation, Inc.

------

Just as Onto Innovation, Inc. protects its own confidential information, we respect the confidential information of others.

This offer of employment is conditioned upon:

oSatisfactory results of a criminal/educational background check and professional references.

oExecution of our Confidentiality Agreement

oProviding verification of your eligibility for employment in the United States. Your continued employment is conditioned upon your continued authorization to work in the United States.

oReceipt of final Board approval

Onto Innovation is an at-will employer, which means that either you or Onto Innovation has the right to terminate employment at any time, with or without advance notice, and with or without cause, for any reason.

As this offer pertains to a role in a public company, we would remind you that your acceptance of this role is considered material non-public information. Please do not share this information with your former employer, colleagues, friends and/or family members, except to the extent that they are aware of the confidential nature of this information and have agreed to keep it in strict confidence, until the information is no longer considered material non-public information.

This offer, together with the Onto Innovation Confidentiality Agreement, is the full and complete statement of the parties' understanding, and supersedes any other communication, whether verbal or written, regarding your employment. At-will employment status can only be modified by a written statement signed by you and an Officer of Onto Innovation (or authorized delegate). The offer is valid until **November 1**<sup>st</sup>**, 2024.**

Please acknowledge your acceptance of this offer by signing below.

Ido, we are confident that your experience, leadership, and vision will be a tremendous asset to the organization. The team and I are excited to collaborate towards our mutual growth and success!

Sincerely,

/s/ Michael P. Plisinski

Michael Plisinski CEO

Onto Innovation

# Signature: /s/ Ido Dolev

------

## Exhibit 10.2

Exhibit 10.2

May 16, 2025

Dear Shirley,

I am pleased to offer you the position of Senior Vice President of Customer Success on a Regular, Full-time basis, reporting to me (Mike Plisinski) in our Milpitas, CA location. Your start date is projected to be June 16<sup>th</sup>, 2025; however, it may be later as it is subject to the conditions set forth herein.

Your total rewards package includes the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Your starting salary will be **$16,730.77** per pay period subject to required withholding and deductions, which when annualized is **$435,000.00**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•You will be eligible to participate in the Company's Key Executive Incentive Plan with a cash bonus target of **75%** of your base salary, the terms of which will be approved by the Compensation Committee of the Board of Directors. You will be eligible for the full 2025 plan year incentive. Incentive compensation is based on the achievement of both corporate and personal objectives.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Subject to the terms and conditions of the Onto Innovation 2020 Stock Plan and the approval of the Compensation Committee of the Board of Directors, you will receive a one-time, sign-on Restricted Stock Unit ("RSU") grant with a value of **$1,350,000.00**, which will vest in equal installments over 3 years.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•As a senior executive your participation in the Key Executive Incentive Compensation Plan includes an annual equity grant. These grants are typically made in the March timeframe and though not guaranteed, we'd expect a grant with a value of approximately **$800,000.00** to be extended to you, subject to the annual approval of the Compensation Committee. These grants are awarded as follows: 50% are time-based, vesting in equal

installments over 3 years, and 50% are performance based, contingent on Onto Innovation's stock performance as compared with the SOXX index as of the 2- and 3-year anniversaries of the grant date. All annual grants are subject to the terms of the Onto Innovation 2020 Stock Plan. You will be eligible for your first equity grant in FY 2025

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Executive benefits also include:

oReimbursement for tax preparation services

oNorton/LifeLock advanced Executive Privacy Support

oAnnual airline club membership

Onto Innovation, Inc. has an excellent benefits program including Health, Dental, Vision, Life and Short and Long-Term Disability insurance coverage. Onto Innovation, Inc. will pay a portion of the cost of your insurance coverage and a portion of your dependents' coverage in accordance with the terms of the applicable benefit plans. Onto Innovation, Inc. may modify benefits from time to time at its sole discretion.

This offer is a result of your individual skills and talent and not for any trade secrets or proprietary information, you may have gained elsewhere. Please do not bring any confidential materials belonging to third parties to Onto Innovation, Inc. Just as Onto Innovation, Inc. protects its own confidential information, we respect the confidential information of others.

------

This offer of employment is conditioned upon:

oSatisfactory results of a criminal/educational background check and professional references.

oExecution of our Confidentiality Agreement

oProviding verification of your eligibility for employment in the United States. Your continued employment is conditioned upon your continued authorization to work in the United States.

oReceipt of final Board approval

Onto Innovation is an at-will employer, which means that either you or Onto Innovation has the right to terminate employment at any time, with or without advance notice, and with or without cause, for any reason.

As this offer pertains to a role in a public company, we would remind you that your acceptance of this role is considered material non-public information. Please do not share this information with your former employer, colleagues, friends and/or family members, except to the extent that they are aware of the confidential nature of this information and have agreed to keep it in strict confidence, until the information is no longer considered material non-public information.

This offer, together with the Onto Innovation Confidentiality Agreement, is the full and complete statement of the parties' understanding, and supersedes any other communication, whether verbal or written, regarding your employment. At-will employment status can only be modified by a written statement signed by you and an Officer of Onto Innovation (or authorized delegate). The offer is valid until **May 21**<sup>st</sup> **, 2025.**

Please acknowledge your acceptance of this offer by signing below.

Shirley, we are confident that your experience, leadership, and vision will be a tremendous asset to the organization. The team and I are excited to collaborate towards our mutual growth and success!

Sincerely,

/s/ Michael P. Plisinski

Michael Plisinski CEO

Onto Innovation

# Signature: /s/ Shirley Chen

------

## Exhibit 31.1

# Exhibit 31.1
**Rule 13a-14(a) Certification of Chief Executive Officer<br>Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002**

I, Michael P. Plisinski, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Onto Innovation Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 5, 2026

---

| | |
|:---|:---|
| By: | /s/ Michael P. Plisinski |
|  | **Michael P. Plisinski** |
|  | **Chief Executive Officer** |

---

------

## Exhibit 31.2

# Exhibit 31.2
**Rule 13a-14(a) Certification of Chief Financial Officer<br>Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002**

I, Brian K. Roberts, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Onto Innovation Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 5, 2026

---

| | |
|:---|:---|
| By: | /s/ Brian K. Roberts |
|  | **Brian K. Roberts** |
|  | **Chief Financial Officer** |

---

------

## Exhibit 32.1

# Exhibit 32.1
**CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

I, Michael P. Plisinski, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Onto Innovation Inc. on Form 10-Q for the period ended March 31, 2026 fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934 and that the information contained in the Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of Onto Innovation Inc.

Date: May 5, 2026

---

| | |
|:---|:---|
| By: | /s/ Michael P. Plisinski |
|  | **Michael P. Plisinski** |
|  | **Chief Executive Officer** |

---

------

## Exhibit 32.2

# Exhibit 32.2
**CERTIFICATION OF CHIEF FINANCIAL OFFICER**

**PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

I, Brian K. Roberts, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Onto Innovation Inc. on Form 10-Q for the period ended March 31, 2026 fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934 and that the information contained in the Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of Onto Innovation Inc.

Date: May 5, 2026

---

| | |
|:---|:---|
| By: | /s/ Brian K. Roberts |
|  | **Brian K. Roberts** |
|  | **Chief Financial Officer** |

---

------